Enabling Investments (SDD)
Abstract
The Enabling Investments System Development & Demonstration (SDD) Project provides the capability to rapidly develop, manufacture, and approve medical countermeasures through sustaining the Department of Defense advanced development manufacturing facility. Enabling efforts in this area support dedicated infrastructure capabilities, demonstrations, and overarching development support functions as portfolio enablers responding to emerging threats. Additional efforts facilitate incorporation of chemical and biological (CB) survivability equipment into Service major acquisition programs. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. EN5 efforts in FY 2022 remain in Projects DE5 and MB5. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts. Efforts included in this Project are: (1) Chem Bio Incident Preparedness and Response - Advanced Development and Manufacturing (CBIPR-ADM) (2) Major Defense Acquisition Program (MDAP) The CBIPR-ADM ensures prioritization to domestic biopharmaceutical manufacturing capacities, capabilities, and infrastructure (e.g. the DoD-ADM Facility and other strategic partners) that are operationally ready to rapidly develop and manufacture medical countermeasures (MCMs) against current and emerging chemical and biological threats including pandemic response. Prioritization is achieved by establishing and enhancing proven biopharmaceutical manufacturing platform technologies and infrastructure at these facilities. Thus, these facilities will have the capability to accelerate development of MCMs at all stages of development, enhance preparedness for existing threats, and rapidly respond to emerging threats as part of a medical integrated layered defense. MCMs that benefit from these efforts include: Vaccines for Viral Agents, Vaccines for Bacterial Agents and Toxins, monoclonal antibodies, antibody fragments and conjugates for therapeutic and prophylactic use across all agent classes. Funds to support prioritization and operational readiness were previously provided via individual product development and manufacturing funding lines. The Department is now providing dedicated funds. The CBIPR-ADM return on investment is an increased level of preparedness and responsiveness. In FY24, the CBIPR-ADM program continues to establish and enhance new manufacturing platform technologies and infrastructure that will enable the development of MCMs against chemical and biological threats. The MDAP Chemical Biological Radiological and Nuclear (CBRN) Survivability Initiative ensures weapon system programs at all Acquisition Category (ACAT) levels, as well as non-DoD agency programs such as those at the Department of Homeland Security (DHS), meet their CBRN defense requirements. This effort facilitates and coordinates the research, development, test and evaluation, procurement, delivery, and life cycle sustainment of affordable CBRN defense materiel solutions for each program's documented CBRN requirements.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2024
- Source ID
- EN5_0604384BP_5_0400_PB_2024
Related Documents
- Root: Chemical and Biological Defense Program - EMD
- Child Accomplishment: 1) CBIPR-ADM
- Child Accomplishment: 2) MDAP
- Child Cost Item: b05ad869ad9c412c1824d04c2762a5cf
- Child Cost Item: 707448ccf0ff3548c9c61ebce4138ad7
- Child Cost Item: 5d5e5ec4a5ddae0caa49dbd340a7394f
- Child Cost Item: 294a456cf2a4ee068c777f890824546c
- Child Cost Item: 68d5358e2161f9e20e318da8eb98b2d0